X

Clinical Trials

Contact Us

GI Cancer

SWOG 1613

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification


URCC 16092 (NCT033186638)

Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy


A021502 (NCT02912559)

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair


EA2161 (NCT02893930)

A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)


RTOG 0848 – Open at MBMC – RT credentialing required for affiliate sites prior to patient registration

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma


A021501 (NCT02839343) (temporarily suspended effective 5/9/18)

Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas


NRG RTOG1112 (NCT01730936) – PENDING RT CREDENTIALING

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma


NRG GI001 (NCT02200042)

Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma


NRG GI002 (NCT02921256) – ONLY AVAILABLE CURRENTLY AT MBMC – MUST BE RT CREDENTIALED. Temporarily suspended 2/12/18

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer


NCTG N1048 (PROSPECT) (NCT01515787) – ONLY AVAILABLE AT MBMC – MUST BE RT CREDENTIALED

A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)